Evidence map›Paper›PMID 37241887›Full record

ArticleMolecules (Basel, Switzerland)2023

Synthesis of Chitosan Oligosaccharide-Loaded Glycyrrhetinic Acid Functionalized Mesoporous Silica Nanoparticles and In Vitro Verification of the Treatment of APAP-Induced Liver Injury.

Xinghua Guo, Chengcheng Zhang, Yan Bai, Qishi Che, Hua Cao, Jiao Guo, Zhengquan Su

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Mesoporous Silica Nanoparticles as Drug Delivery Systems.Pharmaceuticals (Basel, Switzerland) · 2025
    Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Xinghua GuoGuangdong Engineering Research Center of Natural Products and New Drugs, Guangdong Pharmaceutical University, Guangzhou 510006, China.
Chengcheng ZhangGuangdong Engineering Research Center of Natural Products and New Drugs, Guangdong Pharmaceutical University, Guangzhou 510006, China.
Yan BaiSchool of Public Health, Guangdong Pharmaceutical University, Guangzhou 510310, China.
Qishi CheGuangzhou Rainhome Pharm & Tech Co., Ltd., Science City, Guangzhou 510663, China.
Hua CaoSchool of Chemistry and Chemical Engineering, Guangdong Pharmaceutical University, Zhongshan 528458, China.
Jiao GuoGuangdong Metabolic Disease Research Center of Integrated Chinese and Western Medicine, Guangdong Pharmaceutical University, Guangzhou 510006, China.
Zhengquan SuGuangdong Engineering Research Center of Natural Products and New Drugs, Guangdong Pharmaceutical University, Guangzhou 510006, China.ORCID 0000-0001-6324-6620
Guangdong Pharmaceutical University · CN

Funding

not applicable 2020B1515020026not applicable 202103000089
6 · The paper itself

Abstract

objectivethe study was to find a suitable treatment for acute drug-induced liver injury. The use of nanocarriers can improve the therapeutic effect of natural drugs by targeting hepatocytes and higher loads.

methodsfirstly, uniformly dispersed three-dimensional dendritic mesoporous silica nanospheres (MSNs) were synthesized. Glycyrrhetinic acid (GA) was covalently modified on MSN surfaces through amide bond and then loaded with COSM to form drug-loaded nanoparticles (COSM@MSN-NH

resultsGA was successfully modified to obtain the spherical nano-carrier MSN-NH

conclusionthis study demonstrated for the first time that formulation and delivery schemes using natural drug COSM and nanocarrier MSN have a protective effect on APAP-induced hepatocyte injury. This result provides a potential nano-delivery scheme for the targeted therapy of acute drug-induced liver injury.

Indexed as

Chemical and Drug Induced Liver Injury, ChronicChitosanGlycyrrhetinic AcidNanoparticlesDrug CarriersDrug Delivery SystemsHumansOligosaccharidesPorositySilicon DioxideChitosanDrug CarriersGlycyrrhetinic AcidOligosaccharidesSilicon Dioxideacetaminophenchitosan oligosaccharidedrug-induced liver injuryglycyrrhetinic acid modificationmesoporous silica

Identifiers

PMID37241887
PMCPMC10224134
OpenAlexW4377104568

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.